128 related articles for article (PubMed ID: 36203575)
1. Case report: Two PD-L1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after PD-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two cases.
Shang L; Li P; Fan J; Zhao C; Niu X; Bian Q; Yuan Z; Kong Y; Zhu T; Xu B; Dong J; Xiang H
Front Immunol; 2022; 13():946266. PubMed ID: 36203575
[TBL] [Abstract][Full Text] [Related]
2. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
3. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
4. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ
Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296
[TBL] [Abstract][Full Text] [Related]
5. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
6. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis.
Shimura M; Mizuma M; Hayashi H; Mori A; Tachibana T; Hata T; Iseki M; Takadate T; Ariake K; Maeda S; Ohtsuka H; Sakata N; Morikawa T; Nakagawa K; Naitoh T; Kamei T; Motoi F; Unno M
Surg Case Rep; 2017 Dec; 3(1):132. PubMed ID: 29285651
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
8. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
9. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
10. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy analysis of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer.
Song D; Yang X; Guo X; Sun H
Immunotherapy; 2022 Nov; 14(16):1307-1313. PubMed ID: 36341552
[TBL] [Abstract][Full Text] [Related]
12. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
[TBL] [Abstract][Full Text] [Related]
13. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
14. Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma.
Klein O; Brown WA; Saxon S; Haydon A
Oncologist; 2021 Jun; 26(6):461-464. PubMed ID: 33856094
[TBL] [Abstract][Full Text] [Related]
15. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases.
Wang G; Zhou D
Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389
[TBL] [Abstract][Full Text] [Related]
16. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center.
Mita N; Iwashita T; Ichikawa H; Iwasa Y; Uemura S; Murase K; Shimizu M
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34199125
[TBL] [Abstract][Full Text] [Related]
18. A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer.
Dai H; Liu M; Li X; Li T; Huang W; Liao J; Li Y; Fang S
World J Surg Oncol; 2022 Aug; 20(1):267. PubMed ID: 36008813
[TBL] [Abstract][Full Text] [Related]
19. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
20. Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature.
Qiu L; Liu C; Li H
Anticancer Drugs; 2024 Mar; 35(3):263-270. PubMed ID: 38194502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
